CRISPR-Cas-Based Genome Editing for Treating Human Diseases - Part B

Vijai Singh editor

Format:Hardback

Publisher:Elsevier Science Publishing Co Inc

Published:29th Jan '25

Currently unavailable, currently targeted to be due back around 8th April 2025, but could change

CRISPR-Cas-Based Genome Editing for Treating Human Diseases - Part B cover

CRISPR-Cas-Based Genome Editing for Treating Human Diseases, Part B represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems have been proven to be a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. Chapters in this release include Current approaches in CRISPR –Cas systems for metabolic disorders, Recent progress in CRISPR –Cas systems for CRISPR for retinal diseases, Recent progress in CRISPR –Cas systems for cataract and blindness, Advances in CRISPR –Cas systems for muscular dystrophy, Recent development in CRISPR –Cas systems for cardiac disease, Current approaches in CRISPR –Cas systems for diabetes, and much more. Additional sections cover Advances in CRISPR –Cas systems for liver disease, Advances in CRISPR –Cas systems for lung disease, Advances in CRISPR –Cas systems for kidney diseases, Current progress in CRISPR –Cas systems for rare disease, Advances in CRISPR –Cas systems for heredity disease, Recent progress in CRISPR –Cas systems for neurological disorders, and CRISPR challenges in clinical developments.

ISBN: 9780443224201

Dimensions: unknown

Weight: 450g

308 pages